Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab Monotherapy and in Combination With Balstilimab in Advanced Cancer
NCT03860272Phase 1Active, not recruiting
- Sponsor
- Agenus Inc.
- Start
- Mar 2019
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of botensilimab in cancer, angiosarcoma, colorectal cancer (CRC) and 8 more (3 arms), sponsored by Agenus Inc. Primary endpoints: Incidence Of Treatment-emergent Adverse Events up to 2 years, Dose-Limiting Toxicity at 28 days and 1 more. Started Mar 2019; status: active, not recruiting.
02
Drugs
botensilimab
03
Conditions
cancerangiosarcomacolorectal cancer (CRC)endometrial cancer (EC)fibrolamellar carcinoma (FLC)
Beyond the preview
Go deeper on NCT03860272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860272.